SavedAdd your journal

Journals / Çukurova Anestezi ve Cerrahi Bilimler Dergisi / 2026 / Cilt: 9 Sayı: 3

Evaluation of Oncologic Patients with Suspected Lesions on Planar Bone Scintigraphy Using SPECT/CT

Planar kemik sintigrafisinde şüpheli hastalık saptanan onkolojik hasta grubunun SPECT/BT ile değerlendirilmesi

Ebru Salmanoğlu(Adana Şehir Hastanesi)0000-0003-3183-4625
İrfan Peksoy(Ankara Özel Koru Hastanesi, Nükleer Tıp Birimi)0000-0001-5057-8597
Pages
1087–1094
Publication Date
2026-09-30
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The sensitivity, specificity, PPV, NPV, and overall diagnostic accuracy of SPECT/CT were 97.3%, 86.3%, 75.3%, 98.7%, and 89.6%, respectively (p<0.001).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: This study aimed to evaluate the diagnostic accuracy of SPECT/CT to clinical management in oncologic patients with indeterminate lesions on planar bone scintigraphy.
📊
Key Findings & Data:Methods: A total of 1170 oncologic patients who underwent planar bone scintigraphy between March 2010 and September 2012 were retrospectively reviewed.
💡
Conclusion & Impact:The sensitivity, specificity, PPV, NPV, and overall diagnostic accuracy of SPECT/CT were 97.3%, 86.3%, 75.3%, 98.7%, and 89.6%, respectively (p<0.001).
🔬Design:Review & Systematic Survey
📍Scope:2010 Verileri
⚙️Variables:Kemik sintigrafisi · SPECT/BT · kemik metastazı

Abstract

Aim: This study aimed to evaluate the diagnostic accuracy of SPECT/CT to clinical management in oncologic patients with indeterminate lesions on planar bone scintigraphy. Methods: A total of 1170 oncologic patients who underwent planar bone scintigraphy between March 2010 and September 2012 were retrospectively reviewed. Benign and malignant lesions could be differentiated on planar bone scintigraphy in 670 patients, whereas the remaining 500 patients with indeterminate findings were included in the study. The final diagnosis was established by clinical follow-up, diagnostic CT, MRI, F-18 FDG PET/CT, biopsy, or a combination of these reference standard methods. Results: Of the 500 patients included in the study, 261 were male and 239 were female, with a mean age of 59.5±14.3 years. Based on SPECT/CT findings, 306 patients (61.2%) were classified as benign, 129 (25.8%) as malignant, and 65 (13.0%) as indeterminate. Of the 306 patients classified as benign on SPECT/CT, 4 (0.8%) were subsequently confirmed to have bone metastases, whereas 4 (0.8%) of the 129 patients classified as malignant were ultimately diagnosed as benign. Of the 65 patients with indeterminate SPECT/CT findings, 21 (4.2%) were confirmed to have malignant lesions, whereas 44 (8.8%) were found to have benign lesions. The sensitivity, specificity, PPV, NPV, and overall diagnostic accuracy of SPECT/CT were 97.3%, 86.3%, 75.3%, 98.7%, and 89.6%, respectively (p<0.001). Conclusion: SPECT/CT improves diagnostic accuracy in oncologic patients with indeterminate findings on planar bone scintigraphy and provides significant clinical value in the evaluation of skeletal lesions, particularly by markedly increasing specificity.

Özet

Amaç: Bu çalışmada, planar kemik sintigrafisinde belirsiz lezyon saptanan onkolojik hastalarda SPECT/BT'nin tanısal doğruluğunun ve klinik yönetime katkısının değerlendirilmesi amaçlandı. Yöntem: Mart 2010 ile Eylül 2012 tarihleri arasında planar kemik sintigrafisi uygulanan toplam 1170 onkolojik hasta retrospektif olarak incelendi. Planar kemik sintigrafisi ile 670 hastada benign ve malign lezyonlar ayırt edilebilirken, belirsiz bulgular saptanan kalan 500 hasta çalışmaya dahil edildi. Nihai tanı; klinik izlem, tanısal BT, MRG, F-18 FDG PET/BT, biyopsi veya bu referans standart yöntemlerin kombinasyonu ile doğrulandı. Bulgular: Çalışmaya dahil edilen 500 hastanın 261'i erkek, 239'u kadın olup yaş ortalaması 59,5±14,3 yıl idi. SPECT/BT bulgularına göre 306 hasta (%61,2) benign, 129 hasta (%25,8) malign ve 65 hasta (%13,0) belirsiz olarak sınıflandırıldı. SPECT/BT'de benign olarak değerlendirilen 306 hastanın 4'ünde (%0,8) daha sonra kemik metastazı doğrulanırken, malign olarak sınıflandırılan 129 hastanın 4'ü (%0,8) nihai değerlendirmede benign olarak tanımlandı. SPECT/BT bulguları belirsiz olan 65 hastanın 21'inde (%4,2) malign lezyon doğrulanırken, 44'ünde (%8,8) benign lezyon saptandı. SPECT/BT'nin duyarlılığı, özgüllüğü, pozitif prediktif değeri, negatif prediktif değeri ve genel tanısal doğruluğu sırasıyla %97,3, %86,3, %75,3, %98,7 ve %89,6 olarak hesaplandı (p<0,001). Sonuç: SPECT/BT, planar kemik sintigrafisinde belirsiz bulgular saptanan onkolojik hastalarda tanısal doğruluğu artırmakta ve özellikle özgüllüğü belirgin ölçüde yükselterek iskelet lezyonlarının değerlendirilmesinde önemli klinik katkı sağlamaktadır.

🔖

Cite This Article

Salmanoğlu, E., Peksoy, İ. (2026). Evaluation of Oncologic Patients with Suspected Lesions on Planar Bone Scintigraphy Using SPECT/CT. Çukurova Anestezi ve Cerrahi Bilimler Dergisi, Cilt: 9 Sayı: 3, 1087–1094. https://doi.org/10.36516/jocass.1986880

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (30)

  1. Akdağ R, Tosun N, Çinal A, Yeşilyurt H, Şencan İ, Koç O, ve ark. Türkiye’de Özellikli Planlama Gerektiren Sağlık Hizmetleri 2011-2023, T.C. Sağlık Bakanlığı Tedavi Hizmetleri Genel Müdürlüğü, Sağlık Bakanlığı. Yayın No: 836, Ankara, 2011:35-37. https://khgmsaglikhizmetleridb.saglik.gov.tr/TR-42884/turkiyede-ozellikli-planlama-gerektiren-saglik-hizmetleri-2011-2023.html
  2. Ömür Ö, Kapulu C, Uğur Ö. Kas İskelet Sistemi Hastalıklarında Nükleer Tıp Yöntemleri. TOTBİD (Türk Ortopedi ve Travmatoloji Birliği Derneği) Dergisi. 2007;6(1-2):1-29.
  3. Ryan PJ, Fogelman I. The bone scan: where are we now? Semin Nucl Med. 1995;25(2):76-91. doi: 10.1016/s0001-2998(95)80020-4.
  4. Collier BD Jr, Hellman RS, Krasnow AZ. Bone SPECT. Semin Nucl Med. 1987;17(3):247-66. doi: 10.1016/s0001-2998(87)80037-5.
  5. Schillaci O, Simonetti G. Fusion imaging in nuclear medicine--applications of dual-modality systems in oncology. Cancer Biother Radiopharm. 2004;19(1):1-10. doi: 10.1089/108497804773391621.
  6. Chua S, Gnanasegaran G, Cook GJ. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009;39(6):416-30. doi: 10.1053/j.semnuclmed.2009.07.002.
  7. Savelli G, Maffioli L, Maccauro M, De Deckere E, Bombardieri E. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med. 2001;45(1):27-37.
  8. Roach PJ, Schembri GP, Ho Shon IA, Bailey EA, Bailey DL. SPECT/CT imaging using a spiral CT scanner for anatomical localization: Impact on diagnostic accuracy and reporter confidence in clinical practice. Nucl Med Commun. 2006;27(12):977-87. doi: 10.1097/01.mnm.0000243372.26507.
  9. Schillaci O, Danieli R, Manni C, Simonetti G. Is SPECT/CT with a hybrid camera useful to improve scintigraphic imaging interpretation? Nucl Med Commun. 2004;25(7):705-10. doi: 10.1097/01.mnm.0000130240.83949.54.
  10. Even-Sapir E, Flusser G, Lerman H, Lievshitz G, Metser U. SPECT/multislice low-dose CT: a clinically relevant constituent in the imaging algorithm of nononcologic patients referred for bone scintigraphy. J Nucl Med. 2007;48(2):319-24.
  11. Ingui CJ, Shah NP, Oates ME. Endocrine neoplasm scintigraphy: added value of fusing SPECT/CT images compared with traditional side-by-side analysis. Clin Nucl Med. 2006;31(11):665-72. doi: 10.1097/01.rlu.0000242599.22310.d2.
  12. Keidar Z, Israel O, Krausz Y. SPECT/CT in tumor imaging: technical aspects and clinical applications. Semin Nucl Med. 2003;33(3):205-18. doi: 10.1053/snuc.2003.127310.
  13. Tagliabue L, Schillaci O. SPECT/CT in oncology: the fusion of two imaging modalities is a new standard of care. Q J Nucl Med Mol Imaging. 2007;51(4):285-9.
  14. Schillaci O. Hybrid SPECT/CT: a new era for SPECT imaging? Eur J Nucl Med Mol Imaging. 2005;32(5):521-4. doi: 10.1007/s00259-005-1760-9.
  15. Horger M, Bares R. The role of single-photon emission computed tomography/computed tomography in benign and malignant bone disease. Semin Nucl Med. 2006;36(4):286-94. doi: 10.1053/j.semnuclmed.2006.05.001.
  16. Horger M, Eschmann SM, Pfannenberg C, Vonthein R, Besenfelder H, Claussen CD, et al. Evaluation of combined transmission and emission tomography for classification of skeletal lesions. AJR Am J Roentgenol. 2004;183(3):655-61. doi: 10.2214/ajr.183.3.1830655.
  17. Gnanasegaran G, Barwick T, Adamson K, Mohan H, Sharp D, Fogelman I. Multislice SPECT/CT in benign and malignant bone disease: when the ordinary turns into the extraordinary. Semin Nucl Med. 2009;39(6):431-42. doi: 10.1053/j.semnuclmed.2009.07.005.
  18. Zhao Z, Li L, Li F, Zhao L. Single photon emission computed tomography/spiral computed tomography fusion imaging for the diagnosis of bone metastasis in patients with known cancer. Skeletal Radiol. 2010;39(2):147-53. doi: 10.1007/s00256-009-0764-0.
  19. Utsunomiya D, Shiraishi S, Imuta M, Tomiguchi S, Kawanaka K, Morishita S, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology. 2006;238(1):264-71. doi: 10.1148/radiol.2373041358.
  20. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005;46(8):1356-67.
  21. Strobel K, Burger C, Seifert B, Husarik DB, Soyka JD, Hany TF. Characterization of focal bone lesions in the axial skeleton: performance of planar bone scintigraphy compared with SPECT and SPECT fused with CT. AJR Am J Roentgenol. 2007;188(5):W467-74. doi: 10.2214/AJR.06.1215.
  22. Chowdhury FU, Scarsbrook AF. The role of hybrid SPECT-CT in oncology: current and emerging clinical applications. Clin Radiol. 2008;63(3):241-51. doi: 10.1016/j.crad.2007.11.008.
  23. Römer W, Nömayr A, Uder M, Bautz W, Kuwert T. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med. 2006;47(7):1102-6.
  24. Minoves M. Bone and joint sports injuries: the role of bone scintigraphy. Nucl Med Commun. 2003;24(1):3-10. doi: 10.1097/00006231-200301000-00002.
  25. Iqbal B, Currie GM, Wheat JM, Raza H, Kiat H. The incremental value of SPECT/CT in characterizing solitary spine lesions. J Nucl Med Technol. 2011;39(3):201-7. doi: 10.2967/jnmt.111.088351.
  26. Hasegawa BH, Wong KH, Iwata K, Barber WC, Hwang AB, Sakdinawat AE, et al. Dual-modality imaging of cancer with SPECT/CT. Technol Cancer Res Treat. 2002;1(6):449-58. doi: 10.1177/153303460200100605.
  27. Sharma P, Kumar R, Singh H, Bal C, Julka PK, Thulkar S, et al. Indeterminate lesions on planar bone scintigraphy in lung cancer patients: SPECT, CT or SPECT-CT? Skeletal Radiol. 2012;41(7):843-50. doi: 10.1007/s00256-011-1304-2.
  28. Helyar V, Mohan HK, Barwick T, Livieratos L, Gnanasegaran G, Clarke SE, et al. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging. 2010;37(4):706-13. doi: 10.1007/s00259-009-1334-3.
  29. Zhang Y, Shi H, Gu Y, Xiu Y, Li B, Zhu W, et al. Differential diagnostic value of single-photon emission computed tomography/spiral computed tomography with Tc-99m-methylene diphosphonate in patients with spinal lesions. Nucl Med Commun. 2011;32(12):1194-200. doi: 10.1097/MNM.0b013e32834bd82e.
  30. Martí-Bonmatí L, Sopena R, Bartumeus P, Sopena P. Multimodality imaging techniques. Contrast Media Mol Imaging. 2010;5(4):180-9. doi: 10.1002/cmmi.393.